Shots:

• The US FDA has granted approval to the company’s Altius Direct Electrical Nerve Stimulation System, with its commercialization anticipated in H2’24
• The system was assessed under the QUEST trial that reached its efficacy & safety endpoints, significant & lasting pain reduction as well as reduced opioid use with improved quality of life when compared to active-sham control
• The system helps manage chronic phantom and residual limb pain in adult amputees. It comprises of a nerve cuff electrode (placed around affected nerve) and an implantable pulse generator & uses Neuros' patented technology to inhibit pain signals from damaged nerves

Ref: Neuros Medical  | Image: Neuros Medical

Related Post:- Johnson & Johnson Gains the CHMP’s Positive Opinion for Rybrevant (Amivantamab) as a 1L Treatment of NSCLC

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com